Search
tislelizumab
Indications:
- as monotherapy or adjunct to chemotherapy* for treatment of squamous cell carcinoma of the lung
- as monotherapy in patients with previously treated advanced non-small cell lung cancer (NSCLC) [2]
* paclitaxel + carboplatin
Dosage:
- 200 mg administered intravenously every 3 weeks
Mechanism of action:
- high binding affinity to the PD-1 receptor
- specifically engineered to minimize Fc-gamma receptor binding on macrophages
- this diminishes antibody-dependent phagocytosis, a mechanism of T-cell clearance & potential resistance to anti-PD-1 therapy
- antitumor with advanced lung cancers, regardless of PD-L1 expression
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
antineoplastic monoclonal antibody
References
- Wang J, Lu S, Yu X et al
Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for
Advanced Squamous Non-Small-Cell Lung Cancer. A Phase 3 Randomized Clinical Trial.
JAMA Oncol. Published online April 1, 2021
PMID: 33792623
https://jamanetwork.com/journals/jamaoncology/fullarticle/2777901
- Bankhead C
New Anti-PD1 Drugs Boost Survival in Treated Lung Cancer.
Questions about generalizability of results with China-developed therapies.
MedPage Today April 14, 2021
https://www.medpagetoday.com/meetingcoverage/aacr/92100
- Zhou C et al
Results from RATIONALE 303: A global phase III study of tislelizumab
vs docetaxel as second- or third-line therapy for patients with locally
advanced or metastatic NSCLC.
American Association for Cancer Research (AACR) 2021; Abstract CT039